3. november 2007

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

<strong>Investigational compound reduces risk of majorcardiovascular events by 19 percent- significantly improves netclinical benefit despite increased bleeding</strong>

<br />TOKYO and INDIANAPOLIS- Nov. 4 /PRNewswire/ -- In the pivotal PhaseIII head-to-head TRITON TIMI-38 clinical trial- the investigationalantiplatelet agent prasugrel produced a highly significant 19percent reduction in relative risk (p=0.0004) for the compositeendpoint of cardiovascular death- non-fatal heart attack ornon-fatal stroke when compared with clopidogrel(Plavix(R)/Iscover(R)) in the treatment of patients across the fullspectrum of acute coronary syndrome undergoing percutaneouscoronary intervention. A significant reduction in the risk for thecomposite endpoint favoring prasugrel (60 mg loading dose/10 mgmaintenance dose) over clopidogrel (300 mg LD/75 mg MD) wasobserved as early as three days. The absolute difference in thisendpoint continued to increase over the course of the 15-month-13-608-patient trial. In the important subgroup of patients withdiabetes- prasugrel reduced the relative risk of cardiovasculardeath- non-fatal myocardial infarction and non-fatal stroke by 30percent (p lt;0.001). In addition- in the key secondary endpoint ofstent thrombosis- prasugrel reduced the recurrence of stentthrombosis (a new clot that develops at the stent site) by 52percent (p lt;0.0001).